ArticleNature2024
Automated real-world data integration improves cancer outcome prediction.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Machine learning approaches for EGFR mutation status prediction in NSCLC: an updated systematic review.Frontiers in oncology · 2025Pooled it
- High-throughput signal detection of hepatotoxic drug-drug interactions in hospitalized elderly patients: an NLP-driven pharmacovigilance study.Annals of medicine · 2026Article
- Population-Scale Precision Safety in Oncology Reveals Clinical and Genetic Determinants of Systemic Therapy Toxicity.medRxiv : the preprint server for health sciences · 2026Article
- Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer.Cancer cell · 2026Article
- Development and External Validation of a Machine Learning-Based Bleeding Risk Score for Patients Undergoing Percutaneous Coronary Intervention.Circulation reports · 2026Article
- Article
- Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC.Nature medicine · 2026Observational
- Age-stratified mutation patterns in early-onset colorectal cancer reveal distinct molecular features and therapeutic implications.ESMO gastrointestinal oncology · 2026Article
- SMARCA4, STK11, and KEAP1 co-inactivation associates with poor prognosis and upregulation of the TGF-β pathway in lung adenocarcinoma.Translational oncology · 2026Article
- Patient-Level KRAS G12C Prevalence among Hispanic/Latino and Non-Hispanic White Patients in Real-world Clinicogenomic Cohorts.Cancer research communications · 2026Article
- Modality-specific survival outcomes of biomarker-matched therapy in unresected non-small cell lung cancer: a clinicogenomic cohort study.Translational lung cancer research · 2026Article
- SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities.Cancer discovery · 2026Article
- New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.Breast (Edinburgh, Scotland) · 2026Review
- Living Inorganic Nanomaterials: Design, Preparation, and Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Liquid biopsies reveal dual compartments of cancer risk from tumor and host-derived mutations.Bioinformatics (Oxford, England) · 2026Article
- Evolving patterns of co-mutations from tumor initiation to metastatic progression.Nature genetics · 2026Article
- Article
- Interpretable deep learning model of circulating genomics for quantitative survival prediction in advanced non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Review
- APOBEC mutational signatures predict immune checkpoint inhibitor benefit in TMB-low metastatic NSCLC independent of PD-L1 status.ESMO open · 2026Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
69 authors.
Justin Jee *Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9783-0139
Christopher Fong *Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Karl Pichotta *Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Thinh Ngoc Tran *Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3428-2507
Anisha Luthra *Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michele WatersMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5416-5172
Chenlian FuMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2755-4359
Mirella AltoeMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Si-Yang LiuMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Steven B MaronMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Mehnaj AhmedMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Susie KimMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Mono PirunMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-7845-8060
Walid K ChatilaMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5474-218X
Ino de BruijnMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5427-4750
Arfath PashaMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Ritika KundraMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6723-2859
Benjamin GrossMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Brooke MastrogiacomoMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Tyler J ApratiDana Farber Cancer Institute, Boston, MA, USA.
David LiuDana Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-0346-5033
JianJiong GaoCaris Life Sciences, Irving, TX, USA.ORCID 0000-0002-5739-1781
Marzia CapellettiCaris Life Sciences, Irving, TX, USA.
Kelly PekalaMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Lisa LoudonMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Maria PerryMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8789-251X
Chaitanya BandlamudiMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1108-4919
Mark DonoghueMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4538-6069
Baby Anusha SatravadaMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Axel MartinMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Ronglai ShenMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9694-584X
Yuan ChenMemorial Sloan Kettering Cancer Center, New York, NY, USA.
A Rose BrannonMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4610-0149
Jason ChangMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Lior BraunsteinMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Anyi LiMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-1238-2072
Anton SafonovMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Aaron StonestromMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-0602-1158
Pablo Sanchez-VelaMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9286-8290
Clare WilhelmMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2437-5387
Mark RobsonMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3109-1692
Howard ScherMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6791-9324
Marc LadanyiMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9055-7213
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center, New York, NY, USA.
David B SolitMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6614-802X
David R JonesMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3318-0146
Daniel GomezMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Helena YuMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-0377-9510
Debyani ChakravartyMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8629-5732
Rona YaegerMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7233-5454
Wassim AbidaMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Wungki ParkMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8006-3102
Eileen M O'ReillyMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8076-9199
Julio Garcia-AguilarMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2451-0948
Nicholas SocciMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Francisco Sanchez-VegaMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2990-4893
Jian Carrot-ZhangMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-0103-9965
Peter D StetsonMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Ross LevineMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7884-1905
Charles M RudinMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5204-3465
Michael F BergerMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3882-5000
Sohrab P ShahMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6402-523X
Deborah SchragMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Pedram RazaviMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4236-0576
Kenneth L KehlDana Farber Cancer Institute, Boston, MA, USA.
Bob T LiMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6661-8733
Gregory J RielyMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Nikolaus SchultzMemorial Sloan Kettering Cancer Center, New York, NY, USA. schultzn@mskcc.org.ORCID 0000-0002-0131-4904
MSK Cancer Data Science Initiative Group
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0MInvestigational Cancer Therapeutics Training Program (ICTTP)T32CA009207 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Omar Abdel-Wahab, Alexander Drilon · 1985 to 2026
$13.7MProject 3: Predictors of sensitivity to immunotherapy and targeted treatments based on real world evidenceP01CA275746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHARLES L. SAWYERS · 2024 to 2026
$9.4MThe Impact of DNA Damage Repair Abnormalities in Prostate CancerP01CA228696 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2019 to 2024
$8.7MMSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3MBRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinomaR01CA217169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2018 to 2022
$2.5MTargeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinomaR01CA240472 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2019 to 2023
$2.4MDefining mechanisms of resistance to hormonal therapy in breast cancerR01CA234361 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT, SOLIT, DAVID B. · 2019 to 2023
$2.0MAutomatic integrated biomarkers to improve prediction of lung cancer outcomesK08CA286842 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Justin Jee · 2024 to 2026
$769kNCI NIH HHS K08 CA286842NCI NIH HHS K12 CA184746NCI NIH HHS P01 CA228696NCI NIH HHS P01 CA275746NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA217169NCI NIH HHS R01 CA234361NCI NIH HHS R01 CA240472NCI NIH HHS T32 CA009207
Abstract
The digitization of health records and growing availability of tumour DNA sequencing provide an opportunity to study the determinants of cancer outcomes with unprecedented richness. Patient data are often stored in unstructured text and siloed datasets. Here we combine natural language processing annotations
Indexed as
Natural Language ProcessingNeoplasmsAutomationDatasets as TopicElectronic Health RecordsFemaleGenomicsHistone-Lysine N-MethyltransferaseHumansImmunotherapyMachine LearningMaleModels, BiologicalNeoplasm MetastasisPrognosisRegistriesHistone-Lysine N-MethyltransferaseSETD2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.